indinavir-sulfate and Abdominal-Pain

This study evaluates the safety and potential pharmacokinetic interaction between indinavir and trimethoprim/sulfamethoxazole (TMP/SMZ). In a randomized, three-period crossover fashion, 12 healthy adults received 1 week of indinavir sulfate 400 mg orally every 6 hours with placebo, TMP 160 mg/SMZ 800 mg orally every 12 hours with placebo, and indinavir sulfate with TMP/SMZ. Plasma indinavir, SMZ, and TMP concentrations were determined after the last dose of each treatment period. Concomitant administration resulted in a 17% decrease in geometric mean trough plasma indinavir concentrations (p = 0.032), an 18% increase in geometric mean AUC0-12 h and Cmax TMP values (p = 0.031 and 0.030, respectively), and a 5% increase in geometric mean AUC0-12 h SMZ values (p = 0.039). None of these effects was considered clinically significant. The combination of indinavir sulfate and TMP/SMZ is generally well tolerated, with no clinically significant pharmacokinetic interaction being noted.

Topics: Abdominal Pain; Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Area Under Curve; Bilirubin; Cross-Over Studies; Diarrhea; Drug Interactions; Female; Headache; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Trimethoprim, Sulfamethoxazole Drug Combination

Topics: Abdominal Pain; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine

Topics: Abdominal Pain; Acquired Immunodeficiency Syndrome; Adult; Crystallization; Humans; Indinavir; Kidney; Kidney Calculi; Male; Radiography

Topics: Abdominal Pain; Adult; Anti-HIV Agents; Dermatitis, Exfoliative; Fever; HIV Infections; Humans; Indinavir; Male; Renal Insufficiency